Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ghent University
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Sep 8, 2023
Deals
Sept. 8 Quick Takes: Appeals court backs physicians who prescribed ivermectin
Plus: Shanghai TIL play Grit closes $60M B round and deals by Alexion-Verge, Shape-Otsuka and more
BioCentury | Dec 7, 2022
Distillery Therapeutics
A multi-antigen mRNA vaccine for Listeria monocytogenes infection
BioCentury | Dec 11, 2021
Discovery & Translation
New targets at ASH hint at an emerging T cell cancer focus
BioCentury’s ASH21 analysis identifies 22 new targets spanning seven mechanistic categories
BioCentury | Mar 11, 2021
Emerging Company Profile
AgomAb: antibodies driving tissue regeneration and recovery
Emerging Company Profile: argenx spinout AgomAb raises $74M series B to complete clinical POC for lead mAb and grow pipeline
BioCentury | Aug 1, 2020
Emerging Company Profile
VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology
ExeVir emerges with llama-based antibody platform, 1st program for COVID-19
BioCentury | May 1, 2020
Distillery Therapeutics
Apoptosis metabolites for treating arthritis, lung graft rejection
BioCentury | Mar 16, 2020
Product Development
COVID-19 Roundup: Trial starts for Moderna, Sanofi-Regeneron and BioNTech; plus Thermo Fisher, Roche and VIB
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Mar 6, 2020
Deals
Cancer-focused Orionis debuts with small molecule discovery deal with Novartis
BioCentury | Feb 22, 2020
Product Development
COVID-19 mAb menagerie
A taxonomy of mAb programs against COVID-19
BioCentury | Feb 8, 2020
Product Development
Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint
Items per page:
1 - 10 of 39